求購“USPMonographs:Trometamol ”《USP42-NF37》的藥典標(biāo)準(zhǔn)一份.   [更多]

質(zhì)量，進口，注射液   [更多]

Good Clinical Practice: A Question & Answer Reference Guide 2020/2021   [更多]

標(biāo)題： 1.Pharmacokinetics of a Single 150-mg Intravenous Infusion of Fosaprepitant: Effects of Concentration and Infusion Time in Healthy Japanese Men 作者：Azuma, Junichi 1;Fukase, Hiroyuki 2 刊名：Clinical Pharmacology in Drug Development 出版日期：2013 期號：No.4 卷號：Vol.2 2.Pharmacokinetic evaluation of fosaprepitant dimeglumine 作者：Colon-Gonzalez F;Kraft WK. 刊名：Expert Opinion on Drug Metabolism and Toxicology 出版日期：2010 期號：No.10 卷號：Vol.6 3.Pharmacokinetics of Oral Dexamethasone and Midazolam When Administered With Single-Dose Intravenous 150 mg Fosaprepitant in Healthy Adult Subjects 作者：Dr Thomas C. Marbury MD1,*;Ms Phung L. Ngo MS2;Mr Craig R. Shadle MS2;Dr Bo Jin PhD2;Ms Deborah Panebianco MS2;Dr Luzelena Caro PhD2;Dr Jack Valentine PhD2,3;Dr Gail Murphy MD2 刊名：J Clin Pharmacol 出版日期：2011 卷號：Vol.51 4.A Single-Dose Bioequivalence and Food Effect Study With Aprepitant and Fosaprepitant Dimeglumine in Healthy Young Adult Subjects 作者：Craig R. Shadle1,*;M. Gail Murphy1;Yang Liu2;Maureen Ho1;Daniel Tatosian3;Susie (Xiujiang) Li3;Robert A. Blum4 刊名：Clinical Pharmacology in Drug Development 出版日期：2012 期號：No.3 卷號：Vol.1 5.Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy 作者：Bernardo Rapoport;Teresa Smit 刊名：Expert Opinion on Drug Safety 6.Aprepitant and Fosaprepitant Drug Interactions: A Systematic Review. 作者：Patel P;Leeder JS;Piquette-Miller M;Dupuis LL. 刊名：Br J Clin Pharmacol 出版日期：2017 7.Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. 作者：Dr Kenneth C. Lasseter MD1,*;Dr Jay Gambale PharmD2;Dr Bo Jin PhD2;Dr Art Bergman PhD2;Mr Marvin Constanzer MS2;Mr James Dru MS2;Dr Tae H. Han PhD2;Dr Anup Majumdar PhD2;Dr Judith K. Evans MD2;Dr M. Gail Murphy MD2 刊名：The Journal of Clinical Pharmacology 出版日期：2007 期號：NO.7 卷號：Vol.47 8.Prevention of chemotherapy-induced nausea and vomiting:focus on fosaprepitant 作者：Ian N Olver 刊名：Ther Clin Risk Manag 出版日期：2008 期號：No.2 卷號：Vol.4   [更多]

急需“Sertraline hydrochloride”《 EP9.4 》的藥典標(biāo)準(zhǔn)一份.謝謝   [更多]

文獻標(biāo)題: 1.Micronization of Active Pharmaceutical Ingredients (API) – from R&D to the production scale 作者：S Mende 2. Crit Care Med. 2011 Feb;39(2):259-65. doi: 10.1097/CCM.0b013e3181feeb15. Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Boyd JH1, Forbes J, Nakada TA, Walley KR, Russell JA. 3. Crit Care Med. 2006 Feb;34(2):344-53. Sepsis in European intensive care units: results of the SOAP study. Vincent JL1, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D; Sepsis Occurrence in Acutely Ill Patients Investigators. 4.Pharmacokinetic comparison and bioequivalence evaluation of?losartan/ hydrochlorothiazide tablet between Asian Indian and Japanese volunteers. Kumar S,?Monif T,?Khuroo A,?Reyar S,?Jain R,?Singla AK,?Kurachi K. 5.Flow cytometric basophil activation test by detection of CD63 expression in patients with immediate-type reactions to betalactam antibiotics 6.Dev Sci. 2014 Nov;17(6):977-83. doi: 10.1111/desc.12171. Epub 2014 Mar 17. Follow the liar: the effects of adult lies on children's honesty. Hays C1, Carver LJ. 7.Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects. 要求: 打包上傳符合要求的文獻的PDF格式   [更多]

levocarnitine標(biāo)準(zhǔn)原文的全部內(nèi)容   [更多]

正在查找該標(biāo)準(zhǔn)乳果糖口服溶液JX20020289，謝謝提供電子版文件。   [更多]

需求文獻： 1、DAWSON PA， KARPEN SJ． Bile acids reach out to the spinal cord： new insights to the pathogenesis of itch and analgesia in cholestatic liver disease ［J］． Hepatology， 2014， 59 （4）：1638－1641． 2、Kremer AE, van Dijk R, Leckie P, et al. Serum autotaxin is increased in pruirtus of cholestasis, but not of other oirgin, and responds to therapeutic interventions[J]. Hepatology, 2012(56): 1391-1400. 3、Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis. Sumeyye Samur,Matthew Klebanoff,Reiner Banken,Daniel S. Pratt. 《Hepatology》 , 2017 , 65 (3) :920. 4、Obeticholic acid for PBC. Hugh Thomas. Nature Reviews Gastroenterology & Hepatology 13, 558-559 (2016). 5、Emerging and future therapies for nonalcoholic steatohepatitis in adults. Gesthimani Mintziori , Stergios A. Polyzos. 《Expert Opinion on Pharmacotherapy》 , 2016 , 17 (14) :1 -10. 6、9、Obeticholic acid for the treatment of primary biliary cirrhosis. Trivedi PJ, Hirschfield GM, Gershwin ME. Expert Rev Clin Pharmacol. 2016;9(1):13-26. doi:10.1586/17512433.2015.1092381. Epub 2015 Nov 7. 7、Kowdley K，Nevens F，Andreone P，et al． The first new trials for primary biliary cirrhosis in a decade: an international program evaluating the farnesoid X receptor agonist obeticholic acid［J］． Gastroenterology，2015，1481 ( 4) : S991-S992． 8、Treatment of Non-Alcoholic Fatty Liver Disease . Scherer A., Dufour J.-F. 9、Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers. Pencek R, Marmon T, Roth JD, Liberman A, Hooshmand-Rad R, Young MA. Diabetes Obes Metab. 2016 Sep;18 (9):936-40. doi: 10.1111/dom.12681. Epub 2016 Jun 6. 10、Metabolite profiling of CHO?cells with different growth characteristic 11、Sun, Zhaoyun; Peng, Xinhua; Dong, Xiongzi; Shi, Wenwen - Asian Journal of Chemistry, 2012, vol. 24, # 2, p. 929 - 930 要求：下載符合需求的文獻PDF格式打包上傳   [更多]

求購“USP Monographs: Atorvastatin Calcium Tablets”《 USP41-NF36 》的藥典標(biāo)準(zhǔn)一份.   [更多]